BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update Analysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA

Reports Third Quarter 2023 Financial Results and Provides Business Update

of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month

received FDA Fast Track designation in August

1 data recently presented at the North American Cystic Fibrosis Conference (NACFC)

MA and NESS ZIONA, Israel - Nov 14, 2023 - BiomX Inc. (NYSE American: PHGE) ("BiomX"

or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic

bacteria, today reported financial results and provided a business update for the third quarter ended September 30, 2023.

to the continued execution of our clinical team, we are now analyzing data from Part 2 of the Phase 1b/2a trial of BX004 and expect to

announce the results later this month," said Jonathan Solomon, Chief Executive Officer of BiomX. "I am also pleased to note

that the positive data from Part 1 of our trial has been well received by physicians and patient advocacy groups at several prominent

medical meetings, reflecting the need to develop innovative new therapies for combating these persistent and deadly lung infections.

In addition, the U.S. Food and Drug Administration recently granted Fast Track designation for BX004, further underscoring the potential

of this promising program.

a reminder, Part 2 of the trial is evaluating BX004 in a larger number of cystic fibrosis patients who are dosed twice a day and over

a longer, 10-day treatment period compared to Part 1 of the trial. Part 2 of the trial will provide additional clinical data on safety

and reduction in bacterial burden, along with other exploratory clinical endpoints, all of which will help us guide our clinical development

strategy for the program. In light of the expected readout of the Part 2 data, we are forgoing our usual earnings call and will instead

host a conference call and webcast following the release of the Part 2 data."

Dermatitis ("AD") (BX005)

Quarter 2023 Financial Results

the close proximity between the Company's third quarter earnings report and the expected announcement of the Part 2 data from the

Phase 1b/2a trial, BiomX management will forgo holding a call to review its third quarter 2023 earnings and will instead host a conference

call and webcast following the release of the Part 2 data.

is a clinical-stage company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment

of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For

more information, please visit www.biomx.com, the content of which does not form a part of this press release.

press release contains express or implied "forward-looking statements" within the meaning of the "safe harbor"

provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as:

"target," "believe," "expect," "will," "may," "anticipate," "estimate,"

"would," "positioned," "future," and other similar expressions that predict or indicate future events

or trends or that are not statements of historical matters. For example, when BiomX discusses the

potential safety or efficacy of BX004, the expected timing of announcement of results from Part 2 of the Phase 1b/2a trial, the

potential benefits from Fast Track designation for BX004, and the potential of targeted phage therapy to treat infections in CF

patients, the potential timeline for the program to treat

Atopic Dermatitis, and when it discusses the estimate of the sufficiency of its cash runway, BiomX is making forward-looking statements.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management's

current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent

uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of BiomX's control.

Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, investors should

not rely on any of these forward-looking statements and should review the risks and uncertainties described under the caption "Risk

Factors" in BiomX's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC")

on March 29, 2023 and additional disclosures BiomX makes in its other filings with the SEC, which are available on the SEC's website

at www.sec.gov. Forward-looking statements

are made as of the date of this press release, and except as provided by law BiomX expressly disclaims any obligation or undertaking

to update forward-looking statements.

LifeSci Advisors, LLC

Corporate Project Manager

CONSOLIDATED BALANCE SHEETS

in thousands, except share and per share data)

CONSOLIDATED STATEMENTS OF OPERATIONS

in thousands, except share and per share data)